184 related articles for article (PubMed ID: 28254528)
1. Candidate immune biomarkers for radioimmunotherapy.
Levy A; Nigro G; Sansonetti PJ; Deutsch E
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):58-68. PubMed ID: 28254528
[TBL] [Abstract][Full Text] [Related]
2. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
Music M; Prassas I; Diamandis EP
Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
[TBL] [Abstract][Full Text] [Related]
3. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
5. Next generation predictive biomarkers for immune checkpoint inhibition.
Khagi Y; Kurzrock R; Patel SP
Cancer Metastasis Rev; 2017 Mar; 36(1):179-190. PubMed ID: 27873079
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
7. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
8. Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.
Lhuillier C; Vanpouille-Box C; Galluzzi L; Formenti SC; Demaria S
Semin Cancer Biol; 2018 Oct; 52(Pt 2):125-134. PubMed ID: 29258856
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive markers for the new immunotherapies.
Mahoney KM; Atkins MB
Oncology (Williston Park); 2014 Nov; 28 Suppl 3():39-48. PubMed ID: 25384886
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
11. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
[TBL] [Abstract][Full Text] [Related]
12. Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.
Vanpouille-Box C; Formenti SC; Demaria S
Clin Cancer Res; 2018 Jan; 24(2):259-265. PubMed ID: 28751442
[TBL] [Abstract][Full Text] [Related]
13. Immune mechanisms mediating abscopal effects in radioimmunotherapy.
Rodriguez-Ruiz ME; Rodriguez I; Leaman O; López-Campos F; Montero A; Conde AJ; Aristu JJ; Lara P; Calvo FM; Melero I
Pharmacol Ther; 2019 Apr; 196():195-203. PubMed ID: 30529041
[TBL] [Abstract][Full Text] [Related]
14. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
15. Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.
Bou-Dargham MJ; Sha L; Sang QA; Zhang J
BMC Cancer; 2020 Jun; 20(1):572. PubMed ID: 32552802
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
17. Abscopal effect in radioimmunotherapy.
Ashrafizadeh M; Farhood B; Eleojo Musa A; Taeb S; Rezaeyan A; Najafi M
Int Immunopharmacol; 2020 Aug; 85():106663. PubMed ID: 32521494
[TBL] [Abstract][Full Text] [Related]
18. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
Chen K; Ye H; Lu XJ; Sun B; Liu Q
Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
[TBL] [Abstract][Full Text] [Related]
19. Can immunostimulatory agents enhance the abscopal effect of radiotherapy?
Levy A; Chargari C; Marabelle A; Perfettini JL; Magné N; Deutsch E
Eur J Cancer; 2016 Jul; 62():36-45. PubMed ID: 27200491
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
Antonia SJ; Vansteenkiste JF; Moon E
Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
